Search results
Results from the WOW.Com Content Network
Numerous clinical trials have been performed to assess the use of dopamine agonists for the treatment of restless legs syndrome (RLS). RLS is identified by the strong urge to move and is a dopamine-dependent disorder. RLS symptoms decrease with the use of drugs that stimulate dopamine receptors and increase dopamine levels, such as dopamine ...
Dopamine receptors are a class of G protein-coupled receptors that are prominent in the vertebrate central nervous system (CNS) and are implicated in many neurological processes, including motivational and incentive salience, cognition, memory, learning, and fine motor control, as well as modulation of neuroendocrine signaling.
Dopamine receptor agonists can be divided into non-selective dopamine receptor agonists, D 1-like receptor agonists, and D 2-like receptor agonists. Non-selective dopamine receptor agonists include dopamine, deoxyepinephrine (epinine), dinoxyline, and dopexamine. They are mostly peripherally selective drugs, are often also adrenergic receptor ...
These agents stimulate dopamine receptors. In doing so, they alleviate the symptoms associated with Parkinson's disease . Wikimedia Commons has media related to Dopamine agonists .
A new drug has shown promise in alleviating symptoms. (Getty Images) Tavapadon, a drug being tested to treat early Parkinson's disease, ... [medication targeting specific dopamine receptors] for ...
The primary endogenous agonists of the sympathetic nervous system are the catecholamines (i.e., epinephrine [adrenaline], norepinephrine [noradrenaline], and dopamine), which function as both neurotransmitters and hormones. Sympathomimetic drugs are used to treat cardiac arrest and low blood pressure, or even delay premature labor, among other ...
Dopamine therapy is the regulation of levels of the neurotransmitter dopamine through the use of either agonists, or antagonists; and has been used in the treatment of disorders characterized by a dopamine imbalance. Dopamine replacement therapy (DRT) is an effective treatment for patients with decreased levels of dopamine.
By acting as an agonist for the D 2, D 3, and D 4 dopamine receptors, Pramipexole may directly stimulate the underfunctioning dopamine receptors in the striatum, thereby restoring the dopamine signals needed for proper functioning of the basal ganglia. Pramipexole can increase growth hormone indirectly through its inhibition of somatostatin. [37]